MDWD 17.58 MediWound Ltd.
| Range: | 7.45-24.0 | Vol Avg: | 60787 | Last Div: | 0 | Changes: | -0.53 |
| Beta: | 0.83 | Cap: | 0.19B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Mar 20 2014 | Empoloyees: | 100 | ||
| CUSIP: | M68830104 | CIK: | 0001593984 | ISIN: | IL0011316309 | Country: | IL |
| CEO: | Mr. Ofer Gonen B.Sc. | Website: | https://www.mediwound.com | ||||
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Stock Details
MDWD 28
H.C. Wainwright Reiterates Buy Rating on MediWound Ltd (MDWD)
Swayampakula Ramakanth·Fri Oct 11 2024
H.C. Wainwright
MDWD 36
Oppenheimer Reiterates Outperform Rating on MediWound Ltd (MDWD)
Francois Brisebois·Wed May 29 2024
Oppenheimer
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow